SCHEMBL1620675

SCHEMBL1620675

CCCN1N=C(C(=O)NC(C)(C)c2ccc(F)cc2)CC1c1cccc(F)c1

nearest known ligand 0.74

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 8/20 0.74
CNR2 P34972 8/20 0.74
MAOB P27338 2/20 0.41
RIPK1 Q13546 2/20 0.40
PDE5A O76074 1/20 0.40
TP53 P04637 1/20 0.39
MAOA P21397 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
PKM P14618 2/20 0.38
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
JAK2 O60674 1/20 0.37
NTRK1 P04629 1/20 0.37
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1621086 0.94 CNR1 (0.85) CNR1CNR2MAOBRIPK1PDE5A
SCHEMBL1621369 0.87 CNR1 (0.76) CNR1CNR2MAOBRIPK1PDE5A
SCHEMBL1619989 0.85 CNR1 (0.74) CNR1CNR2PDE5AMAPT
SCHEMBL1621063 0.85 CNR1 (0.66) CNR1CNR2
SCHEMBL1621799 0.85 CNR1 (1.00) CNR1CNR2
SCHEMBL1621214 0.83 CNR1 (0.91) CNR1CNR2
SCHEMBL1621351 0.82 CNR1 (0.81) CNR1CNR2MAOBMAOAKDM4E
SCHEMBL1620765 0.82 CNR1 (0.78) CNR1CNR2
SCHEMBL1620314 0.79 CNR1 (0.73) CNR1CNR2KDM4EALDH1A1
SCHEMBL1619028 0.78 CNR1 (0.82) CNR1CNR2RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160459-A1 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS SOLVAY PHARMACEUTICALS, B.V. 2011-06-30 US disclosed
US-7928134-B2 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists SOLVAY PHARMACEUTICALS B.V. (NL) 2011-04-19 US disclosed
US-7928134-B2 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists SOLVAY PHARMACEUTICALS B.V. (NL) 2011-04-19 US disclosed
EP-2203427-A2 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS Abbott Healthcare Products B.V. (NL) 2010-07-07 EP disclosed
WO-2009037244-A2 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS SOLVAY PHARMACEUTICALS B.V. (NL) 2009-03-26 WO disclosed
US-20090082396-A1 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS SOLVAY PHARMACEUTICALS B.V. 2009-03-26 US disclosed
US-20090082396-A1 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS SOLVAY PHARMACEUTICALS B.V. 2009-03-26 US disclosed
US-20090082396-A1 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS SOLVAY PHARMACEUTICALS B.V. 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160459-A1 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS CNR1, CNR2, HTR5A CNR1 1/4885CNR2 2/4885MAOB 1112/4885
US-20090082396-A1 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS CNR1, CNR2, HTR5A CNR1 1/4885CNR2 2/4885MAOB 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.